{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:56Z","timestamp":1787017016412,"version":"build-2736575974"},"reference-count":36,"publisher":"BMJ","issue":"1","funder":[{"name":"Florida Legislative Grant"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2018,6,11]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    The role of\n                    <jats:italic>Mycobacteriumavium<\/jats:italic>\n                    subspecies\n                    <jats:italic>paratuberculosis<\/jats:italic>\n                    (MAP) in Crohn\u2019s disease (CD) is increasingly accepted as evident by detection of the bacteria in the blood and intestinal tissue from patients with CD, and by supporting data from several open-label anti-MAP treatment studies. Tumour necrosis factor alpha (TNF\u03b1) monoclonal antibodies (anti-TNF\u03b1) have been widely used for CD treatment. Despite the short-term benefit of anti-TNF\u03b1 in controlling CD symptoms, most patients suffer from detrimental adverse effects, including higher susceptibility to mycobacterial infections.\n                    <jats:bold>Methods<\/jats:bold>\n                    We investigated the effect of recombinant cytokines and anti-TNF\u03b1 therapeutics on macrophages infected with clinical MAP strain isolated from CD patient blood. MAP viability was measured in macrophages pulsed with PEGylated and non-PEGylated anti-TNF\u03b1 monoclonal antibodies at concentrations 0 to 50\u2009\u00b5g\/mL and with rTNF\u03b1, rIL-6, rIL-12, rIL-23 and IFN\u03b3 at a final concentration of 1000\u2009U\/mL. Expression of proinflammatory cytokines was measured by RT-PCR following MAP infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Both PEGylated and non-PEGylated forms of anti-TNF\u03b1 increased MAP viability by nearly 1.5 logs. rIL-6 and rIL-12 induced MAP viability at 5.42\u00b10.25\u2009and 4.79\u00b10.14\u2009log CFU\/mL, respectively. In contrast, rTNF\u03b1 reduced MAP survival in infected macrophages by 2.63 logs. Expression of\n                    <jats:italic>TNF\u03b1<\/jats:italic>\n                    ,\n                    <jats:italic>IL-6<\/jats:italic>\n                    and\n                    <jats:italic>IL-12<\/jats:italic>\n                    was upregulated threefold following MAP or\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    infection compared with other bacterial strains (p&lt;0.05), while expression of\n                    <jats:italic>IL-23<\/jats:italic>\n                    and\n                    <jats:italic>IFN\u03b3<\/jats:italic>\n                    was not significant after MAP infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    The data indicate MAP-positive patients with CD receiving anti-TNF\u03b1 treatment could result in favourable conditions for MAP infection, which explains the poor response of many patients with CD to anti-TNF\u03b1 therapy.\n                  <\/jats:p>","DOI":"10.1136\/bmjgast-2018-000216","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T02:25:20Z","timestamp":1531707920000},"page":"e000216","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["TNF\u03b1 inhibitors exacerbate\n                    <i>Mycobacterium paratuberculosis<\/i>\n                    infection in tissue culture: a rationale for poor response of patients with Crohn\u2019s disease to current approved therapy"],"prefix":"10.1136","volume":"5","author":[{"given":"Ahmad","family":"Qasem","sequence":"first","affiliation":[{"name":"Burnett School of Biomedical Sciences, Division of Molecular Microbiology, College of Medicine, University of Central Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A","family":"Naser","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, Division of Molecular Microbiology, College of Medicine, University of Central Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,15]]},"reference":[{"key":"2025073012535855000_5.1.e000216.1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"2025073012535855000_5.1.e000216.2","doi-asserted-by":"crossref","first-page":"gutjnl-2012","DOI":"10.1136\/gutjnl-2012-302311","article-title":"Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study","volume":"62","author":"H\u00f8ivik","year":"2013","journal-title":"Gut"},{"key":"2025073012535855000_5.1.e000216.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.041"},{"key":"2025073012535855000_5.1.e000216.4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/14787210.2017.1328276","article-title":"The alternate effects of anti-TNF\u03b1 therapeutics and their role in mycobacterial granulomatous infection in Crohn\u2019s disease","volume":"15","author":"Qasem","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025073012535855000_5.1.e000216.5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13099-016-0090-8","article-title":"Oxidative stress due to Mycobacterium avium subspecies paratuberculosis (MAP) infection upregulates selenium-dependent GPx activity","volume":"8","author":"Qasem","year":"2016","journal-title":"Gut Pathog"},{"key":"2025073012535855000_5.1.e000216.6","unstructured":"Chamberlin WM , Naser SA . Integrating theories of the etiology of Crohn\u2019s disease. On the etiology of Crohn\u2019s disease: questioning the hypotheses. Med Sci Monit 2006;12."},{"key":"2025073012535855000_5.1.e000216.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1209614"},{"key":"2025073012535855000_5.1.e000216.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.135"},{"key":"2025073012535855000_5.1.e000216.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.01.001"},{"key":"2025073012535855000_5.1.e000216.10","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2025073012535855000_5.1.e000216.11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF\u00a0discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025073012535855000_5.1.e000216.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"2025073012535855000_5.1.e000216.13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01106-06"},{"key":"2025073012535855000_5.1.e000216.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1109201108"},{"key":"2025073012535855000_5.1.e000216.15","first-page":"139","article-title":"Inhibition of phagosome maturation and survival of Mycobacterium avium subspecies paratuberculosis in polymorphonuclear leukocytes from Crohn\u2019s disease patients","volume":"12","author":"Rumsey","year":"2006","journal-title":"Med Sci Monit"},{"key":"2025073012535855000_5.1.e000216.16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.intimp.2015.05.049","article-title":"The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: a meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"2025073012535855000_5.1.e000216.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335"},{"key":"2025073012535855000_5.1.e000216.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.024"},{"key":"2025073012535855000_5.1.e000216.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"2025073012535855000_5.1.e000216.20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel targeted therapies for inflammatory bowel disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"2025073012535855000_5.1.e000216.21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13099-016-0127-z","article-title":"A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn\u2019s disease associated with Mycobacterium avium subspecies paratuberculosis","volume":"8","author":"Qasem","year":"2016","journal-title":"Gut Pathog"},{"key":"2025073012535855000_5.1.e000216.22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1128\/iai.64.3.683-690.1996","article-title":"Immunopathology of tuberculosis: roles of macrophages and monocytes","volume":"64","author":"Fenton","year":"1996","journal-title":"Infect Immun"},{"key":"2025073012535855000_5.1.e000216.23","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.4049\/jimmunol.152.8.4087","article-title":"Pulmonary epithelial cells facilitate TNF-alpha-induced neutrophil chemotaxis. A role for cytokine networking","volume":"152","author":"Smart","year":"1994","journal-title":"J Immunol"},{"key":"2025073012535855000_5.1.e000216.24","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90676-4"},{"key":"2025073012535855000_5.1.e000216.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.2.673"},{"key":"2025073012535855000_5.1.e000216.26","first-page":"120","article-title":"The beneficial effects of localized tumor necrosis factor production in BCG infection","volume":"88","author":"Kindler","year":"1991","journal-title":"Behring Inst Mitt"},{"key":"2025073012535855000_5.1.e000216.27","doi-asserted-by":"publisher","DOI":"10.1038\/nri802"},{"key":"2025073012535855000_5.1.e000216.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"2025073012535855000_5.1.e000216.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"2025073012535855000_5.1.e000216.30","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0336"},{"key":"2025073012535855000_5.1.e000216.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"2025073012535855000_5.1.e000216.32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00430-015-0393-2","article-title":"Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment","volume":"204","author":"Nazareth","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"2025073012535855000_5.1.e000216.33","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91182-4"},{"key":"2025073012535855000_5.1.e000216.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb05997.x"},{"key":"2025073012535855000_5.1.e000216.35","first-page":"47","article-title":"Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease","volume":"228","author":"Holub","year":"1998","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2025073012535855000_5.1.e000216.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.9.4750"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2018-000216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:54:11Z","timestamp":1753905251000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2018-000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,7,15]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/bmjgast-2018-000216"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2018-000216","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}